Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
DMAC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.14 - $6.82
Previous CloseN/A
Volume70.76K
Average Volume (3M)88.92K
Market Cap
$282.65M
Enterprise Value$129.30M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Mar 25, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding42,760,582
10 Day Avg. Volume106,245
30 Day Avg. Volume88,920
Standard Deviation0.24
R-Squared0.10
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-15.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.31K
Enterprise Value/Ebitda-5.37
Forecast
1Y Price Target
$11.00Price Target Upside66.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Diamedica Therapeutics News
PremiumCompany Announcements
DiaMedica Therapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
DiaMedica Therapeutics Advances Trials and Financial Position
---
Bulls Say, Bears Say
Bulls Say
Market PotentialSignificant market share potential exists for DM199 in preeclampsia and acute ischemic stroke, given the limited current treatment options.
Regulatory AdvantagesThe application for Orphan Drug Designation for early-onset preeclampsia could provide additional regulatory and financial advantages for DiaMedica.
Bears Say
Regulatory ChallengesDiaMedica addressed the prior FDA clinical hold for the Phase 2/3 ReMEDy2 trial in AIS, and the trial aims to confirm consistent DM199 safety and functional outcomes.
---
Ownership Overview
33.75% Insiders
3.38% Mutual Funds
― Other Institutional Investors
59.94% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DMAC FAQ
What was Diamedica Therapeutics Inc’s price range in the past 12 months?
Diamedica Therapeutics Inc lowest stock price was $2.14 and its highest was $6.82 in the past 12 months.
What is Diamedica Therapeutics Inc’s market cap?
Diamedica Therapeutics Inc’s market cap is $282.65M.
When is Diamedica Therapeutics Inc’s upcoming earnings report date?
Diamedica Therapeutics Inc’s upcoming earnings report date is Mar 25, 2025 which is in 31 days.
How were Diamedica Therapeutics Inc’s earnings last quarter?
Diamedica Therapeutics Inc released its earnings results on Nov 13, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.155 by $0.005.
Is Diamedica Therapeutics Inc overvalued?
According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Undervalued.
Does Diamedica Therapeutics Inc pay dividends?
Diamedica Therapeutics Inc does not currently pay dividends.
What is Diamedica Therapeutics Inc’s EPS estimate?
Diamedica Therapeutics Inc’s EPS estimate is -0.17.
How many shares outstanding does Diamedica Therapeutics Inc have?
Diamedica Therapeutics Inc has 42,760,582 shares outstanding.
What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?
Diamedica Therapeutics Inc reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.155. Following the earnings report the stock price went down -3.286%.
Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?
Currently, no hedge funds are holding shares in DMAC
---
Diamedica Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (66.41% Upside)
$11.00 (66.41% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
125.59%
12-Months-Change
Fundamentals
Return on Equity
-41.90%
Trailing 12-Months
Asset Growth
-9.66%
Trailing 12-Months
Company Description
Diamedica Therapeutics Inc
DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
---
DMAC Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in clinical programs and protocol updates designed to accelerate trial enrollment and enhance study quality. Financial resources appear sufficient to support ongoing activities. However, there were delays in site activations and increased R&D expenses.Read More>---
DMAC Stock 12 Month Forecast
Average Price Target
$11.00
▲(66.41% Upside)
Technical Analysis
Best Analysts Covering DMAC
1 Year
1 Year Success Rate
10/13 ratings generated profit
1 Year Average Return
+54.21%
reiterated a buy rating 2 months ago
Copying Thomas Flaten's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +54.21% per trade.
---